Revive Therapeutics Ltd. (RVV)

Revive Therapeutics Logo White

Revive Therapeutics

CSE: RVV | OTC: RVVTF 

Revive Therapeutics is focused on the R&D and sale of cannabinoid-based products, recently expanding into the psychedelics industry more broadly.

Revive Therapeutics
$0.5100
5.15%
$0.0200

Latest News

Revive Therapeutics Announces Successful Research Results for Psilocybin to Treat Traumatic Brain Injury and Filing of International Patent Application

March 19, 2021

Revive Therapeutics Acquires Unique Psilocybin Assets

February 17, 2021

Revive Therapeutics Announces Research Collaboration with North Carolina State University for Natural Biosynthesis Enzymatic Platform To Develop Psilocybin

January 14, 2021

Dr. John Fahy Joins Revive Therapeutics as Scientific and Clinical Advisor for COVID-19 FDA Phase 3 Study

December 31, 2020

Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19 with Plans on Emergency Use Access

December 23, 2020

Revive Therapeutics Announces LOI to Acquire PharmaTher’s Psilocybin Program

December 21, 2020

Join our Newsletter

Get the latest Company updates delivered to straight to your inbox.